{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:16:21Z","timestamp":1791504981643,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ijantimicag.2023.106841","type":"journal-article","created":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:47:52Z","timestamp":1683452872000},"page":"106841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Optimal dosing regimen of biapenem based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation in patients with febrile neutropenia and haematological malignancies"],"prefix":"10.1016","volume":"62","author":[{"given":"Qi","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1228-869X","authenticated-orcid":false,"given":"Siliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-1282","authenticated-orcid":false,"given":"Huaijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7933-0309","authenticated-orcid":false,"given":"Lu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7838-5519","authenticated-orcid":false,"given":"Mengying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106841_bib0001","doi-asserted-by":"crossref","first-page":"E785","DOI":"10.3390\/pharmaceutics12090785","article-title":"Population pharmacokinetics of continuous-infusion meropenem in febrile neutropenic patients with hematologic malignancies: dosing strategies for optimizing empirical treatment against Enterobacterales and P. aeruginosa","volume":"12","author":"Cojutti","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0002","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10096-003-0894-6","article-title":"Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center","volume":"22","author":"Velasco","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00001432-200208000-00004","article-title":"Treatment of febrile neutropenia: what is new?","volume":"15","author":"Viscoli","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.thj.6200334","article-title":"Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis","volume":"4","author":"Cherif","year":"2003","journal-title":"Hematol J"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199531","article-title":"Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance","volume":"13","author":"Garcia-Vidal","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0007","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-020-05131-2","article-title":"Risk factors for and clinical outcomes of carbapenem non-susceptible Gram negative bacilli bacteremia in patients with acute myelogenous leukemia","volume":"20","author":"Shin","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0008","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/AAC.36.2.481","article-title":"Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic","volume":"36","author":"Hikida","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0009","series-title":"Omegacin (biapenem) prescribing information [in Japanese]","author":"Meiji","year":"2002"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0010","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200262150-00005","article-title":"Biapenem","volume":"62","author":"Perry","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0011","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jac\/35.1.75","article-title":"Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases","volume":"35","author":"Yang","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0012","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijantimicag.2014.05.011","article-title":"Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions","volume":"44","author":"Lip\u0161","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0013","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/jac\/dkn038","article-title":"Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis","volume":"61","author":"Nomura","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0014","series-title":"Performance standards for antimicrobial susceptibility testing; 23rd informational supplement","year":"2014"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000152459","article-title":"Pharmacokinetic\u2013pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy","volume":"54","author":"Ikawa","year":"2008","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0016","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2710.2008.00908.x","article-title":"Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients","volume":"33","author":"Ikawa","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0017","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijantimicag.2008.03.011","article-title":"Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation","volume":"32","author":"Ikawa","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2015.12.018","article-title":"Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation","volume":"47","author":"Dong","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0019","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1473-3099(08)70228-7","article-title":"Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia","volume":"8","author":"Lortholary","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/BF01700408","article-title":"Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group","volume":"16","author":"Nyhl\u00e9n","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0021","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/AAC.31.9.1420","article-title":"Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients","volume":"31","author":"Drusano","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2023.106841_bib0022","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00228-010-0974-3","article-title":"Modelling and simulation as research tools in paediatric drug development","volume":"67","author":"Bellanti","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0023","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40262-013-0085-2","article-title":"Population pharmacokinetics of sifalimumab, an investigational anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus","volume":"52","author":"Narwal","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2023.106841_bib0024","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/518137","article-title":"Pharmacokinetics and pharmacodynamics of antimicrobials","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cmi.2014.11.022","article-title":"Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey","volume":"21","author":"Trecarichi","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0026","first-page":"665","article-title":"Evaluation and correction of the simplified MDRD formula for predicting glomerular filtration rate in patients with chronic kidney disease","author":"Hao Shi","year":"2006","journal-title":"Chin J Pract Intern Med"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0027","first-page":"478","article-title":"Population pharmacokinetic of biapenem in critically ill patients","volume":"51","author":"Chen","year":"2016","journal-title":"Chin Pharmaceut J"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0028","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput Meth Prog Biomed"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0029","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit \u2013 a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Meth Prog Biomed"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bcp.13431","article-title":"External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients","volume":"84","author":"Mao","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0031","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ijantimicag.2017.07.005","article-title":"Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic\/pharmacodynamic analysis using Monte Carlo simulation","volume":"51","author":"Hang","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0032","first-page":"2521","article-title":"Surveillance of bacterial resistance in China 2015\u20132016 Gram-negative bacteria surveillance report","volume":"33","author":"Li","year":"2017","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.diagmicrobio.2007.01.004","article-title":"Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment","volume":"58","author":"DeRyke","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0034","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijantimicag.2012.09.007","article-title":"Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region","volume":"41","author":"Kiratisin","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0036","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijantimicag.2010.10.024","article-title":"Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific region","volume":"37","author":"Roberts","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0037","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2016.06.017","article-title":"Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic\/pharmacodynamic (PK\/PD) simulation","volume":"50","author":"Asuphon","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0038","first-page":"303","article-title":"Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration","volume":"61","author":"Suyama","year":"2008","journal-title":"Jpn J Antibiotics"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0039","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0040","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/17512433.2015.1034689","article-title":"Pharmacologic and clinical evaluation of posaconazole","volume":"8","author":"Moore","year":"2015","journal-title":"Exp Rev Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105814","article-title":"Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug\u2013drug interactions","volume":"162","author":"Li","year":"2021","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0042","first-page":"821","article-title":"Observation of clinical pharmacokinetics and pharmacodynamics of biapenem for injection with three dosing regimens by Monte Carlo simulation","volume":"41","author":"Zhu","year":"2017","journal-title":"Guizhou Med J"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0043","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5428\/pcar20150406","article-title":"Observation of target acquisition probability of biapenem in different dosing regimens by Monte Carlo simulation","volume":"15","author":"Cai","year":"2015","journal-title":"Pharmaceut Care Res"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0044","first-page":"876","article-title":"Optimization of biapenem administration scheme for patients with severe infection","volume":"18","author":"Xue","year":"2018","journal-title":"Evaluat Anal Drug Use Hosp China"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0045","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/AAC.49.8.3550-3553.2005","article-title":"Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure","volume":"49","author":"Pea","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0046","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1128\/AAC.00891-08","article-title":"Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies","volume":"53","author":"Lamoth","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0047","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000057382","article-title":"Effects of a meat meal on renal sodium handling and sodium balance","volume":"24","author":"Cirillo","year":"1998","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0048","first-page":"2452","article-title":"Surveillance of bacterial drug resistance in a general hospital in Chongqing in 2020","volume":"43","author":"Tang","year":"2022","journal-title":"Int J Infect Med"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0049","first-page":"432","article-title":"National Bacterial Resistance Surveillance (CARST) research report on Gram-negative bacteria surveillance from 2019 to 2020","volume":"38","author":"Li","year":"2022","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0050","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3892\/br.2016.598","article-title":"Analysis of drug resistance in 1,861 strains of Acinetobacter baumannii","volume":"4","author":"Jin","year":"2016","journal-title":"Biomed Rep"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0051","first-page":"506","article-title":"A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China","volume":"5","author":"Xu","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijantimicag.2023.106841_bib0052","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ja.2014.119","article-title":"Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004\u20132011","volume":"68","author":"Zhang","year":"2015","journal-title":"J Antibiotics"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:48:23Z","timestamp":1760377703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0924857923001206"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106841","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal dosing regimen of biapenem based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation in patients with febrile neutropenia and haematological malignancies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106841"}}